secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001787306-23-000109
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis appoints L. Todd Edwards as Chief Commercial Officer; Ayisha Jeter promoted
--------------------------------------------------------------------------------

- Edwards joins from Incyte with 25+ years in dermatology/immunology at UCB and AbbVie.
- He will lead ZORYVE cream launch for plaque psoriasis and prepare for future indications.
- Ayisha Jeter promoted to SVP Marketing and Market Access, reporting to Edwards.
- Edwards receives $500,016 base salary, 45% target bonus, equity grants of 240K options, 60K RSUs, 60K PSUs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000109/0001787306-23-000109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000109/arqt-20230927.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer